ASGCT 2027: A Preview of the World's Largest Gene and Cell Therapy Gathering
What this article covers
- When and Where
- Scheduled for May 3–7, 2027, at the Pennsylvania Convention Center in Philadelphia, with an online component for remote attendees — confirmed by ASGCT's own meeting site and official registration platform as well as independent event listings.
- Scope and Scientific Program
- Scope overlaps heavily with stem cell science and cancer immunotherapy: CAR-T, in vivo and ex vivo gene editing, stem and progenitor cell approaches. The meeting requires peer-reviewed abstracts and features regulators alongside scientists, surfacing more rigorous early-stage data — and just as often, the real limitations, safety signals, and manufacturing hurdles that don't make it into marketing copy.
- Bottom Line
- A genuinely significant checkpoint — not because any single presentation will be a breakthrough, but because the peer-reviewed, regulator-attended format makes it one of the more trustworthy places to watch the field's real progress unfold.
Next spring, thousands of scientists, clinicians, regulators, and industry leaders will converge on Philadelphia for the American Society of Gene & Cell Therapy's (ASGCT) 2027 Annual Meeting — widely regarded as the largest annual gathering devoted specifically to gene and cell therapy.
ASGCT is a nonprofit professional society headquartered in Waukesha, Wisconsin, and publishes the peer-reviewed Molecular Therapy family of journals. The 2026 edition (the Society's 29th) ran roughly 172 sessions across more than 250 hours of in-person and on-demand programming, with accepted abstracts published in Molecular Therapy. The 2027 meeting will mark the Society's 30th.
When and Where
Scheduled for May 3–7, 2027, at the Pennsylvania Convention Center in Philadelphia, with an online component for remote attendees — confirmed by ASGCT's own meeting site and official registration platform as well as independent event listings.
Scope and Scientific Program
Scope overlaps heavily with stem cell science and cancer immunotherapy: CAR-T, in vivo and ex vivo gene editing, stem and progenitor cell approaches. The meeting requires peer-reviewed abstracts and features regulators alongside scientists, surfacing more rigorous early-stage data — and just as often, the real limitations, safety signals, and manufacturing hurdles that don't make it into marketing copy.
ASGCT has not yet published the detailed 2027 scientific program; expected emphasis on CAR-T and engineered immune cell therapies for cancer, advances and setbacks in in vivo gene editing, and cell manufacturing and scalability.
RegenMed Review exists to translate exactly this kind of primary-source scientific meeting into plain language for patients and caregivers; we don't name or recommend specific clinics or providers.
Bottom Line
A genuinely significant checkpoint — not because any single presentation will be a breakthrough, but because the peer-reviewed, regulator-attended format makes it one of the more trustworthy places to watch the field's real progress unfold.
Key Questions Answered
- When and where is ASGCT 2027?
- Scheduled for May 3–7, 2027, at the Pennsylvania Convention Center in Philadelphia, with an online component for remote attendees — confirmed by ASGCT's own meeting site and official registration platform as well as independent event listings.
- What does the meeting cover?
- Scope overlaps heavily with stem cell science and cancer immunotherapy: CAR-T, in vivo and ex vivo gene editing, stem and progenitor cell approaches. The meeting requires peer-reviewed abstracts and features regulators alongside scientists, surfacing more rigorous early-stage data — and just as often, the real limitations, safety signals, and manufacturing hurdles that don't make it into marketing copy.
- Why is the meeting significant?
- A genuinely significant checkpoint — not because any single presentation will be a breakthrough, but because the peer-reviewed, regulator-attended format makes it one of the more trustworthy places to watch the field's real progress unfold.
Sources
- ASGCT Annual Meeting official site, American Society of Gene & Cell Therapy, 2026 — https://annualmeeting.asgct.org/
- ASGCT 2027 Annual Meeting exhibitor information, American Society of Gene & Cell Therapy, 2026 — https://support.annualmeeting.asgct.org/asgct2027/Public/Content.aspx?ID=736
- Future Annual Meetings, American Society of Gene & Cell Therapy, 2026 — https://asgct.org/events/future-annual-meetings
- 29th Annual Meeting (May 2026), American Society of Gene & Cell Therapy, 2026 — https://www.asgct.org/asgct-events/may-2026/29th-annual-meeting
- ASGCT 2027 Annual Meeting listing, Medical College of Wisconsin Stem Cell and Gene Editing (SCGE) program, 2026 — https://scge.mcw.edu/events/asgct-2027-annual-meeting/
Related Articles
- Research & Industry
Why Patient Testimonials Aren't Proof: Understanding the Limits of Anecdotal Evidence at Stem Cell Clinics
Why sincere patient stories cannot establish treatment efficacy, and how selection bias, placebo effects and natural symptom changes can mislead.
- Research & Industry
Exosome Skin Treatments in South Korea: What's Actually Happening
Korea's regulator restricts human-derived exosomes in cosmetics and bans exosome ad claims. What's actually sold in Seoul, and what the safety literature shows.
- Research & Industry
Medical Tourism for Stem Cell Therapy: What to Verify Before You Travel Abroad for Treatment
Traveling abroad for stem cell therapy removes key protections. Learn the specific risks medical tourism adds and what to verify before booking treatment overseas.